Episode 2 Season 1
This month’s Australian Health Journal is a DOUBLE EPISODE with a special report on mental health. Watch interviews from Biplar Australia, Westmead Institute for Medical Research, Conviction Group, The Resilience Centre and TRED College.
Success in WA pilot to observe babies showing delays in social interaction & communication development
Inklings – led by The Kids Research Institute Australia – is a program for babies aged 6-18 months whose communications skills are developing differently to expected milestones. In early 2025 it has completed the first year of a pilot program.
At the time of filming (Nov 2024), Inklings has received more then 300 enquiries across WA and started to deliver services to 160 children, with almost 60 who have completed the program.
Navigating the health system for mental health support
Senior professionals and middle managers are experiencing increased burnout and stress, leading to higher alcohol consumption, and there is a need for better support and resources for mental health and addiction treatment in Australia, according to Ruth Limkin, Founder of The Banyans and Chief Development Officer at parent Sana Health Group.
Investigating use of dietary supplements for osteoarthritis
Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations.
Report gives insights to clinical trial activity in Australia
Established in 2024, Bellberry is a Adelaide-based national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.
Australian Health Journal spoke with Bellberry Limited CEO, Kylie Sproston on the organisation and the findings in activity documented in the Clinical Trial Activity Report (CTAR) 2024.
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.